<collection><source>PMC</source><date>20201214</date><key>pmc.key</key><document><id>34116</id><infon key="license">NO-CC CODE</infon><passage><infon key="article-id_pmc">34116</infon><infon key="article-id_pmid">11438045</infon><infon key="article-id_publisher-id">AR-3-4-259</infon><infon key="fpage">259</infon><infon key="issue">4</infon><infon key="journal-title">Arthritis Research</infon><infon key="kwd">arthritis flow-through high-titer retrovirus interleukin-1 receptor antagonist</infon><infon key="lpage">263</infon><infon key="name_0">surname:Del Vecchio;given-names:Maria A</infon><infon key="name_1">surname:Georgescu;given-names:Helga I</infon><infon key="name_2">surname:McCormack;given-names:James E</infon><infon key="name_3">surname:Robbins;given-names:Paul D</infon><infon key="name_4">surname:Evans;given-names:Christopher H</infon><infon key="section_type">TITLE</infon><infon key="type">front</infon><infon key="volume">3</infon><infon key="year">2001</infon><offset>0</offset><text>Approaches to enhancing the retroviral transduction of human synoviocytes</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>74</offset><text>This report focuses on an experimental design for rheumatoid arthritis, where an amphotropic retrovirus (MFG-IRAP) was used to transfer a cDNA encoding human interleukin-1 receptor (IL-1Ra) to synovium. The protocol required the cells to secrete at least 30 ng of these proteins before reimplantation, and there are several alternative methods available for increasing efficiency in this process.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>1390</offset><text>Introduction</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>1403</offset><text>In this paper we describe a novel approach to enhancing retroviral transduction of human synoviocytes using a novel DNA-guided DNA polymerase chain reaction (PCR) approach.

Our approach involves creating a DNA-guided DNA polymerase chain reaction (DNA-PCR) platform that can be designed to target DNA-binding proteins that are expressed in human synoviocytes. The DNA-PCR platform can be used to target DNA-binding proteins that are expressed in human synoviocytes. The DNA-PCR platform can be designed to target DNA-binding proteins that are expressed in human synoviocytes. The DNA-PCR platform can be designed to target DNA-binding proteins that are expressed in human synoviocytes.

We investigated whether the DNA-PCR platform can target a variety of</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2012</offset><text>For this study we looked at several different ways to find out what is most likely to occur: first, if rabbit type B synoviocytes were transduced with the amphotropic retrovirus MFG-IRAP and under standard, static conditions that they secrete into their culture medium about 100 ng human immunoglobulin-1 (IL-1) virus per day; second a mouse model expressing human IL-1RA/106 cells per nightly time of arrival; and finally we need to establish which conditions would yield the highest transduction efficiency.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_1</infon><offset>2661</offset><text>Materials and Methods</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>2683</offset><text>Cell culture</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>2696</offset><text>Synovial tissue was recovered from joints of five patients undergoing surgery for the management of their RA. Cells were isolated by sequential digestion of synovium with trypsin and collagenase, counted with a hemocytometer, cultured in Ham's F-12 medium supplemented with 10% (v/v) fetal bovine serum and antibiotics, and seeded into 25 cm2 plastic culture flasks with 4 ml medium at a density of 5 &#215; 105 cells per flask (passage 0). Viabilty of &gt;95% was confirmed by staining with trypan blue. Among cells of passage 0, type A and type B synovial fibroblasts and macrophages were the predominant adherent cells and lymphocytes were the predominant nonadherent cells. The latter were removed by medium changes every 3 days. Confluent cells were detached by trypsinizing, washed, and reseeded into 6-well culture plates at a density of 0.5&#8211;1.0 &#215; 105 cells per well (first-passage cells) or into 25 cm2 flasks. When the flasks reached confluence, they were trypsinized and seeded into six-well plates at a density of 0.5&#8211;1.0 &#215; 105 cells per well (second-passage cells). Since type-A synoviocytes and macrophages are lost during trypsinization, passage 1 and passage 2 cells consist of type B synovial fibroblasts.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>3917</offset><text>Vectors</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>3925</offset><text>The construction of a &#936;-CRIP producer line for MFG-IRAP has been previously described. The Human Gene Therapy Applications Laboratory of the University of Pittsburgh Medical Center produced clinical grade virus. The titer of this retroviral preparation was found to be 5 &#215; 105 infectious particles/ml. This preparation is referred to as 'standard titer' retrovirus. High titer MFG-IRAP was produced by concentration using tangential flow filtration and size exclusion chromatography.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>4411</offset><text>MFG-LacZ was also generated using the &#936;-CRIP producer line. This vector contains the &#946;-galactosidase gene, and was used as a marker of gene expression.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>4568</offset><text>Transduction of synoviocytes</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>4597</offset><text>Transductions were carried out in six-well plates on passage 1 or passage 2 cells as noted below. On day 1, cells were plated at a density of 0.5&#8211;1.0 &#215; 105 cells per well. When the cells were 50&#8211;60% confluent, the culture medium was removed and replaced with 3 ml of supernatant containing standard-titer MFG-IRAP, standard titer MFG-LacZ, high titer MFG-IRAP, or medium alone. All transductions were carried out in the presence of Polybrene (8 &#956;g/ml) or dioctadecylamidoglycylspermine (DOGS) (5 &#956;g/ml), as indicated.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>5122</offset><text>For static transductions, viral supernatants were added to the cultures, which then were returned to the incubator for 2 h (one patient), 6 h (one patient) or 12 h (three patients), after which time the viral suspensions were replaced with 3 ml of fresh culture medium. For double static transduction, the media were removed 24 h from the time of the initial transduction and the process was repeated. In another series of experiments, the retroviral supernatants were allowed to remain on the cells for 24, 48, 72, or 96 h, with a change of retroviral supernatant every 24 h. At the end of the transduction period, all cells were washed with Gey's balanced salt solution and then 4 ml of culture medium was added to each well.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>5850</offset><text>For transduction during centrifugation, the plates were centrifuged at 2000 g at 32&#176;C during the 2 h transduction period. Centrifugation resulted in the development of a crescent-shaped 'dry' area in the center of each well. Because the cells in these areas were deprived of liquid during the transduction period, they did not survive. The dry areas were estimated to comprise approximately 10% of the area of the well.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>6271</offset><text>For flow-through transduction, the method of was followed. Briefly, synoviocytes were cultured on collagen-coated inserts (Transwell-COL&#8482; from Costar), which were then placed into six-well plates. Retroviral supernatants (1 ml) were placed in the upper well and allowed to flow through the monolayer under gravity. After 8 h, the cells were washed and culture media were added to the wells.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>6664</offset><text>Gene expression</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>6680</offset><text>After transduction, 4 ml of supplemented Ham's F-12 medium was added to each well, plates were returned to the incubator, and cells were allowed to reach confluence. Once the cells were confluent, the media were removed and the cells were washed with 4 ml Gey's balanced salt solution, which was then replaced with 4 ml culture medium. After 48 h, conditioned media were collected and stored at &#8211;20&#176;C until they were assayed for IL-Ra expression. Cells were trypsinized and counted using a hemocytometer. Concentrations of IL-1Ra in the conditioned media were determined by ELISA (R&amp;D Systems, Minneapolis, MN). Expression of LacZ was ascertained by histochemical staining with 5-bromo-4-chloro-3-indoyl-&#946;-D-galactoside (X-gal) using standard techniques.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>7439</offset><text>Data were analyzed with the statistical software Statview 4.5; unpaired t-tests were used to compare groups.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_1</infon><offset>7548</offset><text>Results</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>7556</offset><text>Four different methods of retroviral transduction of rheumatoid synovium were compared: A) one static transduction at passage 1; B) one static transduction at passage 2; C) transduction at passage 1 during centrifugation; D) two static transductions made 24 h apart during passage 1 (Fig. 1).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>7849</offset><text>Cells transduced once at passage 1 by static infection with standard-titer MFG-IRAP secreted 14.2 &#177; 2.8 ng IL-1Ra/106 cells per 48 h. None of the cultures secreted the &#8805; 30 ng IL-1Ra/106 cells per 48 h required by the clinical protocol. Similar results were obtained with second passage cells. Static transduction twice within a passage resulted in an average secretion of 33.8 &#177; 8.7 ng IL-1Ra/106 cells per 48 h, but only two of the five cultures secreted more than 30 ng/106 cells per 48 h. First passage cells transduced once while being centrifuged secreted 110 &#177; 8.0 ng IL-1Ra/106 cells per 48 h (P &lt; 0.0001 vs one or two static transductions) and all five cultures exceeded the cutoff threshold of 30 ng/106cells per 48 h. Routine static transductions with MFG-LacZ vector, carried out in parallel with these experiments, resulted in approximately 30% LacZ+ cells, whereas transductions carried out during centrifugation resulted in nearly 100% transduction.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>8819</offset><text>Lowering the temperature from 37 to 32&#176;C or increasing the volume of the retroviral supernatant from 1 to 3 ml per well produced small (25% or less; statistically insignificant) improvements in transgene expression (data not shown). Increasing the time of transduction beyond 24 h raised the transduction efficiency considerably (Fig. 2). With transduction periods of 48 and 72 h, all cultures produced at least 30 ng IL-1Ra/106 cells per 48 h.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>9265</offset><text>In another series of experiments, high titer MFG-IRAP, flow-through transduction, and DOGS instead of Polybrene were evaluated for their effects on transduction efficiency and gene expression (Table 1). Qualitatively equivalent results were obtained with two different patients in triplicate experiments. Transduction was significantly more efficient with high titer than with low titer virus, regardless of the polycation used (P &lt; 0.05) or the transduction method (static or flow-through). The flow-through transduction method was significantly better (P &lt; 0.05) than static transduction when Polybrene was used. In the presence of DOGS, flow-through transduction was significantly better than static transduction if low titer virus was used (P &lt; 0.05). Overall, DOGS did not consistently provide significantly better transduction efficiency than Polybrene.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_1</infon><offset>10125</offset><text>Discussion</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>10136</offset><text>These data support a growing body of evidence that centrifuging enhances the efficiency of retroviral transduction. Similar experiments using MFG-LacZ confirmed that centrifuging increased the proportion of transduced cells, suggesting that the main effect is on transduction efficiency. The disadvantage of centrifuging is loss of cells due to the formation of lunate dry areas. Increasing the volume of supernatant minimizes these dry areas, but increases the consumption of supernatant.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>10626</offset><text>Length of exposure to retroviral supernatant also affected transduction. The MFG retroviral vector used in this study is based on the Moloney murine leukemia virus, which provides all the elements necessary for infection of target cells. The half-life of Moloney-based retroviruses at 37&#176;C is 6&#8211;9 h, so they would survive long enough to transduce cells as they entered mitosis during prolonged incubations. The plateau in efficiency between 72 and 96 h of transduction probably reflects the fact that the cells became confluent during that time.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>11175</offset><text>In general, our data using flow-through transduction support those of Chuck and Palsson. The disadvantage of the flow-through method was the need for regular attention to ensure that wells had not run dry and to recycle the viral supernatant. However, the method was economical, because it was possible to cycle 1 ml of supernatant over the cells. Flow-through improved IL-1Ra expression using the lower titer virus, but the degree of enhancement differed between the two patients; in one, there was an approximately 3- to 8-fold increase, depending on whether Polybrene or DOGS was used (Table 1). In the other patient, increases of approximately 20- and 30-fold were obtained. The improving effects of the flow-through method were less dramatic with high titer virus, where transduction was already higher under static conditions, but increases of up to 3-fold were obtained.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>12053</offset><text>Increasing the titer of the retrovirus improved transduction efficiencies 25- to 30-fold when Polybrene was used and approximately 40-fold when DOGS was used. Although the results were not as dramatic as those reported by Themis and colleagues, the use of DOGS instead of Polybrene gave a small to moderate improvement in IL-1Ra production. Overall, the highest levels of transgene expression were obtained using high titer retrovirus in combination with flow-through transduction conditions. These values far exceeded those obtained by centrifuging with standard titer virus. The effects of centrifuging with high titer virus were not evaluated.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_1</infon><offset>12700</offset><text>Remarkable conclusions</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>12712</offset><text>These data indicate that high titer retrovirus leads to the highest increase in retroviral transduction in human synovioviocytes. High reactivity with flow-through transducing or centrifugation of these factors also resulted in an overall increase, for instance, of IL-1Ra production by 50&#8211;100 times compared to static transducts performed with standard tenth-generator virus. This will be especially important when performing gene therapy with such transgenes as AMPs (which are produced in large molar excess over the</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">title_1</infon><offset>13416</offset><text>Abbreviations</text></passage><passage><infon key="section_type">ABBR</infon><infon key="type">paragraph</infon><offset>13430</offset><text>DOGS = dioctadecylamidoglycylspermine; IL-1Ra = interleukin-1 receptor antagonist [protein]; RA = rheumatoid arthritis; SD = standard deviation; SEM = standard error of the mean.</text></passage><passage><infon key="fpage">1</infon><infon key="lpage">16</infon><infon key="name_0">surname:Evans;given-names:CH</infon><infon key="name_1">surname:Ghivizzani;given-names:SC</infon><infon key="name_2">surname:Kang;given-names:R</infon><infon key="name_3">surname:Muzzonigro;given-names:T</infon><infon key="name_4">surname:Wasko;given-names:MC</infon><infon key="name_5">surname:Herndon;given-names:JH</infon><infon key="name_6">surname:Robbins;given-names:PD</infon><infon key="pub-id_pmid">9920008</infon><infon key="section_type">REF</infon><infon key="source">Arthritis Rheum</infon><infon key="type">ref</infon><infon key="volume">42</infon><infon key="year">1999</infon><offset>13609</offset><text>Gene therapy for rheumatic diseases.</text></passage><passage><infon key="fpage">227</infon><infon key="lpage">231</infon><infon key="name_0">surname:Bandara;given-names:G</infon><infon key="name_1">surname:Robbins;given-names:PD</infon><infon key="name_2">surname:Georgescu;given-names:HI</infon><infon key="name_3">surname:Mueller;given-names:GM</infon><infon key="name_4">surname:Glorioso;given-names:JC</infon><infon key="name_5">surname:Evans;given-names:CH</infon><infon key="pub-id_pmid">1567555</infon><infon key="section_type">REF</infon><infon key="source">DNA Cell Biol</infon><infon key="type">ref</infon><infon key="volume">11</infon><infon key="year">1992</infon><offset>13646</offset><text>Gene transfer to synoviocytes: prospects for gene treatment of arthritis.</text></passage><passage><infon key="fpage">1261</infon><infon key="lpage">1280</infon><infon key="name_0">surname:Evans;given-names:CH</infon><infon key="name_1">surname:Robbins;given-names:PD</infon><infon key="name_10">surname:Wasko;given-names:MC</infon><infon key="name_11">surname:Watkins;given-names:SC</infon><infon key="name_12">surname:Whiteside;given-names:TL</infon><infon key="name_13">surname:Glorioso;given-names:JC</infon><infon key="name_14">surname:Lotze;given-names:MT</infon><infon key="name_15">surname:Wright;given-names:TM</infon><infon key="name_2">surname:Ghivizzani;given-names:SC</infon><infon key="name_3">surname:Herndon;given-names:JH</infon><infon key="name_4">surname:Rang;given-names:R</infon><infon key="name_5">surname:Bahnson;given-names:AB</infon><infon key="name_6">surname:Barranger;given-names:JA</infon><infon key="name_7">surname:Elders;given-names:EM</infon><infon key="name_8">surname:Gay;given-names:S</infon><infon key="name_9">surname:Tomaino;given-names:MM</infon><infon key="pub-id_pmid">8793551</infon><infon key="section_type">REF</infon><infon key="source">Hum Gene Ther</infon><infon key="type">ref</infon><infon key="volume">7</infon><infon key="year">1996</infon><offset>13720</offset><text>Clinical trial to assess the safety, feasibility and efficacy of transferring a potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis.</text></passage><passage><infon key="fpage">893</infon><infon key="lpage">900</infon><infon key="name_0">surname:Bakker;given-names:AC</infon><infon key="name_1">surname:Joosten;given-names:LA</infon><infon key="name_2">surname:Arntz;given-names:OJ</infon><infon key="name_3">surname:Helsen;given-names:MM</infon><infon key="name_4">surname:Bendele;given-names:AM</infon><infon key="name_5">surname:van de;given-names:Loo</infon><infon key="name_6">surname:FA van den Berg;given-names:WB</infon><infon key="pub-id_pmid">9153551</infon><infon key="section_type">REF</infon><infon key="source">Arthritis Rheum</infon><infon key="type">ref</infon><infon key="volume">40</infon><infon key="year">1997</infon><offset>13884</offset><text>Prevention of murine collagen-induced arthritis in the knee and ipsilateral paw by local expression of human interleukin-1 receptor antagonist protein in the knee.</text></passage><passage><infon key="fpage">402</infon><infon key="lpage">406</infon><infon key="name_0">surname:Makarov;given-names:SS</infon><infon key="name_1">surname:Olsen;given-names:JC</infon><infon key="name_2">surname:Johnson;given-names:WN</infon><infon key="name_3">surname:Anderle;given-names:SK</infon><infon key="name_4">surname:Brown;given-names:RR</infon><infon key="name_5">surname:Baldwin;given-names:AS;suffix:Jr</infon><infon key="name_6">surname:Haskill;given-names:JS</infon><infon key="name_7">surname:Schwab;given-names:JH</infon><infon key="pub-id_pmid">8552648</infon><infon key="section_type">REF</infon><infon key="source">Proc Natl Acad Sci U S A</infon><infon key="type">ref</infon><infon key="volume">93</infon><infon key="year">1996</infon><offset>14048</offset><text>Suppression of experimental arthritis by gene transfer of interleukin 1 receptor antagonist cDNA.</text></passage><passage><infon key="fpage">3558</infon><infon key="lpage">3562</infon><infon key="name_0">surname:Otani;given-names:K</infon><infon key="name_1">surname:Nita;given-names:I</infon><infon key="name_2">surname:Macaulay;given-names:W</infon><infon key="name_3">surname:Georgescu;given-names:HI</infon><infon key="name_4">surname:Robbins;given-names:PD</infon><infon key="name_5">surname:Evans;given-names:CH</infon><infon key="pub-id_pmid">8617986</infon><infon key="section_type">REF</infon><infon key="source">J Immunol</infon><infon key="type">ref</infon><infon key="volume">156</infon><infon key="year">1996</infon><offset>14146</offset><text>Suppression of antigen induced arthritis in rabbits by ex vivo gene therapy.</text></passage><passage><infon key="fpage">10764</infon><infon key="lpage">10768</infon><infon key="name_0">surname:Bandara;given-names:G</infon><infon key="name_1">surname:Mueller;given-names:GM</infon><infon key="name_2">surname:Galea-Lauri;given-names:J</infon><infon key="name_3">surname:Tindal;given-names:MH</infon><infon key="name_4">surname:Georgescu;given-names:HI</infon><infon key="name_5">surname:Suchanek;given-names:MK</infon><infon key="name_6">surname:Hung;given-names:GL</infon><infon key="name_7">surname:Glorioso;given-names:JC</infon><infon key="name_8">surname:Robbins;given-names:PD</infon><infon key="name_9">surname:Evans;given-names:CH</infon><infon key="pub-id_pmid">8248169</infon><infon key="section_type">REF</infon><infon key="source">Proc Natl Acad Sci U S A</infon><infon key="type">ref</infon><infon key="volume">90</infon><infon key="year">1993</infon><offset>14223</offset><text>Intraarticular expression of biologically active interleukin-1-receptor-antagoinist protein by ex vivo gene transfer.</text></passage><passage><infon key="fpage">1015</infon><infon key="lpage">1022</infon><infon key="name_0">surname:Georgescu;given-names:HI</infon><infon key="name_1">surname:Mendelow;given-names:D</infon><infon key="name_2">surname:Evans;given-names:CH</infon><infon key="pub-id_pmid">2846503</infon><infon key="section_type">REF</infon><infon key="source">In Vitro Cell Dev Biol</infon><infon key="type">ref</infon><infon key="volume">24</infon><infon key="year">1988</infon><offset>14341</offset><text>HIG-82: an established cell line from rabbit periarticular soft tissue, which retains the "activatable" phenotype.</text></passage><passage><infon key="fpage">6460</infon><infon key="lpage">6464</infon><infon key="name_0">surname:Danos;given-names:O</infon><infon key="name_1">surname:Mulligan;given-names:RC</infon><infon key="pub-id_pmid">3413107</infon><infon key="section_type">REF</infon><infon key="source">Proc Natl Acad Sci U S A</infon><infon key="type">ref</infon><infon key="volume">85</infon><infon key="year">1988</infon><offset>14456</offset><text>Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges.</text></passage><passage><infon key="fpage">1</infon><infon key="lpage">60</infon><infon key="name_0">surname:Fong;given-names:TC</infon><infon key="name_1">surname:Sauter;given-names:SL</infon><infon key="name_2">surname:Ibanez;given-names:CE</infon><infon key="name_3">surname:Sheridan;given-names:PL</infon><infon key="name_4">surname:Jolly;given-names:DJ</infon><infon key="pub-id_pmid">10755210</infon><infon key="section_type">REF</infon><infon key="source">Crit Rev Ther Drug Carrier Syst</infon><infon key="type">ref</infon><infon key="volume">17</infon><infon key="year">2000</infon><offset>14558</offset><text>The use and development of retroviral vectors to deliver cytokine genes for cancer therapy.</text></passage><passage><infon key="fpage">743</infon><infon key="lpage">750</infon><infon key="name_0">surname:Chuck;given-names:AS</infon><infon key="name_1">surname:Palsson;given-names:BO</infon><infon key="pub-id_pmid">8919596</infon><infon key="section_type">REF</infon><infon key="source">Hum Gene Ther</infon><infon key="type">ref</infon><infon key="volume">7</infon><infon key="year">1996</infon><offset>14650</offset><text>Consistent and high rates of gene transfer can be obtained using flow-through transduction over a wide range of retroviral titers.</text></passage><passage><infon key="fpage">1180</infon><infon key="lpage">1186</infon><infon key="name_0">surname:Themis;given-names:M</infon><infon key="name_1">surname:Forbes;given-names:SJ</infon><infon key="name_2">surname:Chan;given-names:L</infon><infon key="name_3">surname:Cooper;given-names:RG</infon><infon key="name_4">surname:Etheridge;given-names:CJ</infon><infon key="name_5">surname:Miller;given-names:AD</infon><infon key="name_6">surname:Hodgson;given-names:HJ</infon><infon key="name_7">surname:Coutelle;given-names:C</infon><infon key="pub-id_pmid">9930318</infon><infon key="section_type">REF</infon><infon key="source">Gene Ther</infon><infon key="type">ref</infon><infon key="volume">5</infon><infon key="year">1998</infon><offset>14781</offset><text>Enhanced in vitro and in vivo gene delivery using cationic agent complexed retrovirus vectors.</text></passage><passage><infon key="fpage">131</infon><infon key="lpage">143</infon><infon key="name_0">surname:Bahnson;given-names:AB</infon><infon key="name_1">surname:Dunigan;given-names:JT</infon><infon key="name_2">surname:Baysal;given-names:BE</infon><infon key="name_3">surname:Mohney;given-names:T</infon><infon key="name_4">surname:Atchison;given-names:RW</infon><infon key="name_5">surname:Nimgaonkar;given-names:MT</infon><infon key="name_6">surname:Ball;given-names:ED</infon><infon key="name_7">surname:Barranger;given-names:JA</infon><infon key="pub-id_pmid">8530565</infon><infon key="section_type">REF</infon><infon key="source">J Virol Methods</infon><infon key="type">ref</infon><infon key="volume">54</infon><infon key="year">1995</infon><offset>14876</offset><text>Centrifugal enhancement of retroviral mediated gene transfer.</text></passage><passage><infon key="fpage">6994</infon><infon key="lpage">7000</infon><infon key="name_0">surname:Morgan;given-names:JR</infon><infon key="name_1">surname:LeDoux;given-names:JM</infon><infon key="name_2">surname:Snow;given-names:RG</infon><infon key="name_3">surname:Tompkins;given-names:RG</infon><infon key="name_4">surname:Yarmush;given-names:ML</infon><infon key="pub-id_pmid">7474118</infon><infon key="section_type">REF</infon><infon key="source">J Virol</infon><infon key="type">ref</infon><infon key="volume">69</infon><infon key="year">1995</infon><offset>14938</offset><text>Retrovirus infection: effect of time and target cell number.</text></passage><passage><infon key="fpage">167</infon><infon key="lpage">227</infon><infon key="name_0">surname:Arend;given-names:WP</infon><infon key="pub-id_pmid">8379462</infon><infon key="section_type">REF</infon><infon key="source">Adv Immunol</infon><infon key="type">ref</infon><infon key="volume">54</infon><infon key="year">1993</infon><offset>14999</offset><text>Interleukin-1 receptor antagonist.</text></passage><passage><infon key="section_type">FIG</infon><infon key="type">title_1</infon><offset>15034</offset><text>Figures and Tables</text></passage><passage><infon key="file">AR-3-4-259-1.jpg</infon><infon key="id">F1</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>15053</offset><text>IL-1Ra production by human synoviocytes after transduction by MFG-IRAP under various conditions. Monolayer cultures of synoviocytes from five different patients with RA were transduced with standard-titer MFG-IRAP under the following conditions: A) first passage cells; static conditions; single transduction; B) second passage cells; static conditions; single transduction; C) first passage cells; with centrifuging; single transduction; D) first passage cells; static conditions; double transduction. Each point represents the average of two determinations for each patient under the indicated conditions. To the left of each column are the overall means for each method &#177; SD. The dashed line indicates the minimum level of 30 ng IL-1Ra/106 cells per 48 h required by the clinical protocol. IL-1Ra production after transduction with centrifuging (column C) exceeds all other methods, with P &lt; 0.0001.</text></passage><passage><infon key="file">AR-3-4-259-2.jpg</infon><infon key="id">F2</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>15957</offset><text>IL-1Ra production by human synoviocytes after static transduction for extended periods. Monolayer cultures of synoviocytes from five different patients with RA were transduced statically in duplicate with standard titer MFG-IRAP for the indicated lengths of time. Supernatants were changed every 24 h, until transductions were completed for all cultures. The cells were then washed, given complete media, and incubated for a further 48 h. At this time, media were harvested and IL-1Ra content was determined. Values are means &#177; SD. IL-1Ra production increased significantly (P &lt; 0.05) when the time of transduction was increased from 24 to 48 h and from 48 to 72 h.</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>16624</offset><text>Effect of flow-through, high retroviral titer and DOGS on the transduction of human synoviocytes.</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version="1.0" encoding="UTF-8"?&gt;
&lt;table frame="hsides" rules="groups"&gt;&lt;thead&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align="center" colspan="4"&gt;IL-1Ra production (ng/10&lt;sup&gt;6&lt;/sup&gt; cells per 48 h)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td colspan="4"&gt;&lt;hr/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align="center" colspan="2"&gt;High titer&lt;/td&gt;&lt;td align="center" colspan="2"&gt;Standard titer&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td colspan="2"&gt;&lt;hr/&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;hr/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align="left"&gt;Patient 1&lt;/td&gt;&lt;td align="left"&gt;Patient 2&lt;/td&gt;&lt;td align="right"&gt;Patient 1&lt;/td&gt;&lt;td align="right"&gt;Patient 2&lt;/td&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align="left"&gt;Stationary PB&lt;/td&gt;&lt;td align="left"&gt;235 &#177; 6&lt;/td&gt;&lt;td align="left"&gt;177 &#177; 9&lt;/td&gt;&lt;td align="right"&gt;9 &#177; 1&lt;/td&gt;&lt;td align="right"&gt;6 &#177; 1&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;Flow PB&lt;/td&gt;&lt;td align="left"&gt;721 &#177; 17&lt;/td&gt;&lt;td align="left"&gt;249 &#177; 4&lt;/td&gt;&lt;td align="right"&gt;171 &#177; 6&lt;/td&gt;&lt;td align="right"&gt;17 &#177; 2&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;Stationary DOGS&lt;/td&gt;&lt;td align="left"&gt;299 &#177; 12&lt;/td&gt;&lt;td align="left"&gt;210 &#177; 21&lt;/td&gt;&lt;td align="right"&gt;8 &#177; 1&lt;/td&gt;&lt;td align="right"&gt;5 &#177; 0&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;Flow DOGS&lt;/td&gt;&lt;td align="left"&gt;908 &#177; 105&lt;/td&gt;&lt;td align="left"&gt;258 &#177; 5&lt;/td&gt;&lt;td align="right"&gt;260 &#177; 8&lt;/td&gt;&lt;td align="right"&gt;39 &#177; 3&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>16722</offset><text>	IL-1Ra production (ng/106 cells per 48 h)	 			 		High titer	Standard titer	 				 		Patient 1	Patient 2	Patient 1	Patient 2	 	Stationary PB	235 &#177; 6	177 &#177; 9	9 &#177; 1	6 &#177; 1	 	Flow PB	721 &#177; 17	249 &#177; 4	171 &#177; 6	17 &#177; 2	 	Stationary DOGS	299 &#177; 12	210 &#177; 21	8 &#177; 1	5 &#177; 0	 	Flow DOGS	908 &#177; 105	258 &#177; 5	260 &#177; 8	39 &#177; 3	 	</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>17044</offset><text>Values are means &#177; SEM. Each result is the average of three determinations for each patient. PB = Polybrene.</text></passage></document></collection>